DO-2 vs Vebreltinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline

DO-2

Developed by DeuterOncology

Phase 1 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT05752552 (registry estimate)

No aligned efficacy figure on record for this race.

Vebreltinib

Marketed by Avistone Biotechnology under a licence from Apollomics Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT04258033 · Phase 2 · completed

This is an open-label, single-arm study with no randomization and no comparator group. The response rate in cohort 1 was high and its confidence interval cleared a preset benchmark, but without a control group the size of the drug's effect cannot be judged directly.

Next expected readout: December 2026 · NCT06343064 (registry estimate)

Reported efficacy

Objective response rate (2 years): Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee (met)

Result source: NCT04258033

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDO-2Vebreltinib
PFS, median—Not reported—Trial running · NCT06970782
OS, median—Not reported—Trial running · NCT06970782
ORR—Not reported—Trial running · NCT06970782
Duration of response, median—Not reported—Trial running · NCT06970782

PFS, median

DO-2
—Not reported
Vebreltinib
—Trial running · NCT06970782

OS, median

DO-2
—Not reported
Vebreltinib
—Trial running · NCT06970782

ORR

DO-2
—Not reported
Vebreltinib
—Trial running · NCT06970782

Duration of response, median

DO-2
—Not reported
Vebreltinib
—Trial running · NCT06970782
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

DO-2: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Vebreltinib
Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee NCT04258033 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DO-2's landscape · Vebreltinib's landscape